Semaglutide's chemical structure — and what it tells us about how Wegovy works

Step 1: start with the natural hormone and see what's missing

The story of semaglutide's structure begins with glucagon-like peptide-1 (GLP-1), a hormone your gut releases in the minutes after a meal. GLP-1 signals to the brain that you have eaten, slows the passage of food from the stomach, and prompts the pancreas to release insulin in a glucose-dependent way. Useful chemistry, but GLP-1 itself lasts about two minutes in the bloodstream before the enzyme DPP-4 cleaves it at position 2 and the kidneys clear the fragments. For any medicine to work, that problem has to be solved.

Novo Nordisk's chemists started with the 31-amino-acid GLP-1 sequence and asked what structural changes would preserve function while defeating rapid clearance. The answer involved three modifications, each targeting a different vulnerability, and if you want a closer look at how those components fit together, our page on semaglutide structure walks through each one in detail. Together they shift the half-life from two minutes to approximately one week, long enough for a once-weekly injection. You can explore the broader picture of how the medicine is used for weight management on our Wegovy overview page.

Step 2: three modifications that change everything

The first modification replaces the amino acid alanine at position 8 with alpha-aminoisobutyric acid (Aib). That single substitution blocks DPP-4 from cleaving the peptide, because the enzyme cannot grip the altered site. The molecule now survives long enough for the remaining engineering to matter.

The second modification swaps lysine at position 34 for arginine, reducing binding to unintended receptors.

The third (and most structurally distinctive) is the attachment of a C18 fatty-diacid chain to lysine at position 26, connected via a short hydrophilic linker. This fatty-acid side chain allows semaglutide to bind reversibly to albumin, the most abundant protein in human plasma. While bound, the molecule is shielded from enzymatic attack and too large for the kidneys to filter. It releases slowly, maintaining active drug concentrations between weekly doses. The molecular structure of semaglutide is described in full in the prescribing documentation available on the electronic Medicines Compendium (eMC).

A question our prescribers hear most weeks is whether semaglutide and human GLP-1 are essentially the same thing. They are not. The modifications above are what separate a hormone that vanishes in two minutes from a medicine that stays clinically active for seven days.

Step 3: what the structure means for how you experience the medicine

The fatty-acid linker does more than extend duration: it changes how the molecule distributes across the body. Albumin circulates everywhere, so semaglutide reaches GLP-1 receptors not only in the pancreas but in the hypothalamus (appetite regulation), the brainstem, the stomach wall, and other organs. The result is the multi-system effect seen in clinical trials (reduced hunger, slower gastric emptying, improved glycaemic control) arising from a single receptor type activated in several locations at once.

The gastrointestinal side effects common early in treatment, including nausea, reflect this same wide receptor reach: the stomach wall slows significantly, and the brain's nausea centres are also GLP-1-sensitive. The relationship between semaglutide and stomach symptoms is worth reading if you want to understand why these effects tend to ease as the body adjusts. For the full list of known side effects, the NHS semaglutide medicines page is the clearest patient-level reference.

The oral version of semaglutide (Wegovy tablets) adds another layer of chemistry: the molecule is co-formulated with SNAC (salcaprozate sodium), an absorption enhancer that creates a transient pH rise in the stomach lining to allow the peptide to cross intact. The underlying amino-acid sequence is identical to the injection; the bioavailability challenge is what makes the two formulations different products. Details on what Wegovy costs in the UK can help you compare the options.

Step 4: why structure matters when evaluating semaglutide products

Because semaglutide is a large, modified peptide rather than a small molecule, it cannot be reproduced by straightforward chemical synthesis, its manufacture requires biological processes and rigorous quality control at every step. This is precisely why the MHRA has warned about counterfeit and unverified semaglutide products sold online: a product that looks identical in name and dose may differ at the molecular level in ways that affect both efficacy and safety. The MHRA's Yellow Card scheme allows patients and clinicians to report suspect medicines and potential side effects.

For anyone considering semaglutide for weight management, the relevant UK-licensed forms are Wegovy (subcutaneous injection) and, since June 2026, Wegovy tablets, both prescribed following clinical assessment. Any product claiming to be semaglutide that arrives without a UK prescription from a verified pharmacy carries structural uncertainty as well as legal and safety risks. Our frequently asked questions address common concerns about sourcing and legitimacy. If you'd like to understand whether semaglutide could be suitable for you, speaking to a prescriber is the right first step.